SCHEMBL4492001

SCHEMBL4492001

CN1CCN(c2ccc(Nc3ncc(C(N)=O)cn3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.62
LCK P06239 3/20 0.59
MAPK14 Q16539 3/20 0.59
CDK2 P24941 4/20 0.58
CCNA2 P20248 3/20 0.58
CDK4 P11802 3/20 0.58
AURKA O14965 2/20 0.58
CCNA1 P78396 2/20 0.58
STAT6 P42226 1/20 0.58
CCND3 P30281 1/20 0.58
CDK6 Q00534 1/20 0.58
INSR P06213 1/20 0.57
ALK Q9UM73 1/20 0.57
SLC2A1 P11166 2/20 0.56
PIM1 P11309 1/20 0.56
TTK P33981 1/20 0.56
PIM2 Q9P1W9 1/20 0.56
PTK2 Q05397 1/20 0.55
CCND1 P24385 2/20 0.55
KDR P35968 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28228697 0.88 LCK (0.60) SYKLCKMAPK14CDK4STAT6
SCHEMBL5686069 0.86 SYK (0.53) SYKCDK4INSRALKCCND1
SCHEMBL5686121 0.85 SYK (0.64) SYKCDK2AURKACSF1RBRD4
SCHEMBL5686325 0.85 RAB9A (0.56) SYKLCKMAPK14CDK4CDK6
SCHEMBL4488495 0.85 SYK (0.62) SYKCDK2CCNA2CDK4CCNA1
SCHEMBL4499479 0.84 SYK (0.67) SYKLCKMAPK14CDK4AURKA
SCHEMBL2951233 0.82 ALK (0.62) LCKMAPK14CDK2CCNA2CDK4
SCHEMBL2951338 0.81 LCK (0.76) SYKLCKMAPK14CDK4CCND1
SCHEMBL5686213 0.81 FLT3 (0.58) SYKLCKCDK2AURKAINSR
SCHEMBL28322770 0.80 JAK2 (0.71) SYKCDK2CCNA2CDK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504396-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2009-03-17 US disclosed
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
US-20050209221-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-09-22 US disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209221-A1 Substituted heterocyclic compounds and methods of use ICOS, CD4, HLA-DRB1 SYK 1151/4885LCK 33/4885MAPK14 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.